Drug Trial News

RSS

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago.

30 May 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

FVCG portfolio companies selected to present research at Bio International 2015

Actinobac Biomed, NovoPedics, Inc. and MentiNova, Inc., three biotech start-up companies originally funded with investments from Foundation Venture Capital Group (FVCG), have been selected to present their research at Bio International 2015 as part of the Start-Up Stadium and Company Presentation forums offered at the Conference, announced FVCG President James M. Golubieski.

30 May 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US.

30 May 2015

Guardian Research Network, Molecular Health to provide therapeutic clinical trial access to cancer patients

The Guardian Research Network and Molecular Health have announced a collaboration designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.

29 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma Inc. today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2, 2015 in Chicago, Illinois.

29 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.

29 May 2015

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments.

28 May 2015

Drug Trial News

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

FVCG portfolio companies selected to present research at Bio International 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

Guardian Research Network, Molecular Health to provide therapeutic clinical trial access to cancer patients

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

First European approval of drug to treat genetic kidney disease ADPKD

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Monoclonal antibody nivolumab improves survival rates of melanoma patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Green tea components may help prevent prostate cancer development in at-risk men

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Clementia Pharmaceuticals commences multi-center study of patients with fibrodysplasia ossificans progressiva

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Latest News